Blood-based genetic screening reveals early warning signs across multiple cancers, even those not covered by standard checks.
Detect Cancer Early
Stay One Step Ahead,
Detect Cancer Before It Grows
99% specificity, minimizing false positives—95%+ in recent trials
~40–50% sensitivity for early-stage cancers (Stage I–III)
70% of detected cancers were types without standard screening methods
Why Early Detection Matters
Early Detection Saves Lives
Early-stage breast cancer has a 99% five-year survival, but that drops below 32% if found late.
Early Detection
Detect cancers years before symptoms emerge
Hidden Cancers
Identify cancers standard screenings can’t catch—like ovarian or pancreatic
Better Outcomes
More treatment options and better outcomes when caught early
Survival Rate for 5 Years After Diagnosed
Unfortunately, the current blood test can detect only the later stages of cancer
How SuperDNA Gut Health Test Works
Simple, Powerful, Personalized
Step 1
Provide sample at home or clinic
Step 2
Advanced AI-driven analysis spots cancer DNA
Step 3
Get a clear result, including confidence and next steps
Featured Tests
Get Screened Early
CancerDetect™ – Multi Cancer Early Detection Test
- Detects both common & rare cancers, with >0% sensitivity across 80+ cancer types
- High specificity: >99% accuracy
- Ideal for ages 40+, family history, or after previous treatment
Diagnostic Test Performance Comparison
| Test | Specificity | Sensitivity |
| Liquid Biopsy | High (Approximately 90-99%) | Variable (Approximately 60%-90% or higher in advanced cancer stages) |
| MRI | High (Approximately 85%-95%) | Approximately 80%-95% |
| CT Scan | Moderate High (Approximately 75%-85%) | Approximately 80%-90% |
- Liquid Biopsy tests are highly specific for detecting specific genetic mutations.
- MRI and PET scans are sensitive in identifying anatomical and functional abnormalities associated with cancer and other medical conditions.
CancerDetect™ – Multi Cancer Early Detection Test
- Genetic testing for inherited cancer risk variants (e.g. BRCA, Lynch)
- Even carriers without symptoms can act early with targeted health strategies
- Includes personalized risk report and family guidance
Cancer Risk Screening vs. MCED Test
| Feature | Cancer Risk Screening | MCED Test |
|---|---|---|
| Test Type | Inherited genetic test | Blood-based tumor signal test |
| Purpose | Predict future cancer risk | Detect existing early cancer |
| Frequency | Once (unless new genes are added) | Regularly (e.g. yearly) |
| Results | Risk level (e.g., high, moderate) | Presence or absence of cancer signal |
| Recommended Age Groups | 18+ | 40+ |
| Who is Suitable | • Individuals with family cancer history<br>• People planning preventive measures | • Adults over 40 (especially without standard screening options)<br>• Those with family cancer history<br>• People wanting proactive monitoring |
Real Stories & Impact
The test detected a cancer signal—we caught ovarian cancer at Stage I
In a community study of ~53,000 people, MCED testing flagged early-stage cancers including those without regular screening, with 91% correct tissue prediction .
Half the cancers we detected were types we can’t screen for traditionally—and 50% were stage I/II.
PATHFINDER trial showed 71% of detected cancers lacked standard screening; half were early stage.
The signal appeared before symptoms—now I’m in treatment early.”
Johns Hopkins pilot found cancer signs up to three years before symptoms.
Your Genes Hold Clues—Let Us Help You Find Them
Whether you have a family history or want peace of mind—early detection gives you time and choices.
